Dear Friends and Colleagues,

On behalf of the European Neuroendocrine Tumor Society (ENETS) and our partner NET societies around the world (incl. NANETS, APNETS, COMMNETS, CSNET, CNETS, JNETS, Argentum, NET Initiatives in South America, and INCA), it is a great pleasure to welcome you to this inaugural research event, the 1st World NET Forum - A Forum on Basic, Translational and Global NET Aspects. It is an exciting time for neuroendocrine tumor science as we continue to grow and adapt and innovate. NET societies globally are striving to increase the knowledge surrounding the fundamental scientific aspects pertaining to NET tumors and this forum is aimed at bringing the leading scientists in our field to connect and inspire clinicians and scientists at the cutting edge of NET research.

The 1st World NET Forum will focus on models in NET research, NET tumor biology advances, therapeutic advances in NET and novel areas in NET diagnostics and therapy.

Some of the many highlights awaiting you include keynote speeches on unravelling entero-endocrine differentiation with organoid models, understanding the tumor biology of NEN by integrated genomic analysis, deciphering NET tumor invasiveness to potentiate real therapy candidates, and precision oncological approach in neuroendocrine tumors.

We are delighted and grateful to welcome several leading international NET scientists, who represent a true global perspective in our NET research field; they will deliver insight into bridging the gap between basic, translational and clinical science. The forum will hopefully inspire and germinate future solid scientific endeavours and help in connecting scientists-clinicians in our field going forward.

Finally, I’d like to thank the entire international 1st World NET Forum scientific committee and our prestigious and stellar international faculty for attending this forum and bringing their expertise to our gathering. Throughout this conference, I ask you to stay engaged and proactive and make use of all the opportunities to exchange, learn and network.

With kind regards,

Dermot O’Toole
ENETS Chairman

On behalf of the 1st World NET Forum Scientific Committee
Dear Friends and Colleagues,

On behalf of the European Neuroendocrine Tumor Society (ENETS) and our partner NET societies around the world (incl. NANETS, APNETS, COMNETS, CSNET, CNETS, JNETS, Argentum, NET Initiatives in South America, and INCA), it is a great pleasure to welcome you to this inaugural research event, the 1st World NET Forum - A Forum on Basic, Translational and Global NET Aspects. It is an exciting time for neuroendocrine tumor science as we continue to grow and adapt and innovate. NET societies globally are striving to increase the knowledge surrounding the fundamental scientific aspects pertaining to NET tumors and this forum is aimed at bringing the leading scientists in our field to connect and inspire clinicians and scientists at the cutting edge of NET research.

The 1st World NET Forum will focus on models in NET research, NET tumor biology advances, therapeutic advances in NET and novel areas in NET diagnostics and therapy.

Some of the many highlights awaiting you include keynote speeches on unravelling entero-endocrine differentiation with organoid models, understanding the tumor biology of NEN by integrated genomic analysis, deciphering NET tumor invasiveness to potentiate real therapy candidates, and precision oncological approach in neuroendocrine tumors.

We are delighted and grateful to welcome several leading international NET scientists, who represent a true global perspective in our NET research field; they will deliver insight into bridging the gap between basic, translational and clinical science. The forum will hopefully inspire and germinate future solid scientific endeavours and help in connecting scientists-clinicians in our field going forward.

Finally, I’d like to thank the entire international 1st World NET Forum scientific committee and our prestigious and stellar international faculty for attending this forum and bringing their expertise to our gathering. Throughout this conference, I ask you to stay engaged and proactive and make use of all the opportunities to exchange, learn and network.

With kind regards,

Dermot O’Toole

ENETS Chairman

On behalf of the 1st World NET Forum Scientific Committee
Tuesday, 10 March 2020
12:30 – 13:30 REGISTRATION AND COFFEE
Foyer 1st Floor
13:30 – 14:30 Welcome
Room 112
Dermot O’Toole, IRL
14:30 – 15:30 Session 1: Models in NET Research
Chairs: Aurel Perren, SUI / Simon Singh, CAN
13:40 – 14:20 Keynote Address: Unravelling Enteroid-endocrine Differentiation with Organoid Models
Hans Clevers, NED
14:20 – 14:40 Zebrafish Models in Tumor Mechanisms and in Guiding Therapy: Potential Adaptability to NET
Adam Hurstione, GBR
14:40 – 15:00 2D Models - Differentiation of Intestinal NET Endocrine Cell Phenotypes
Ramesh Divakaruni, USA
15:00 – 15:20 Establishing a Reliable Well-Differentiated NET Tumor Model
Joerg Schrader, GER
15:20 – 15:30 Discussion
15:30 – 15:50 COFFEE BREAK
Room 112
15:50 – 16:50 Session 2: NET Tumor Biology Advances
Chairs: Ya-Chen, CHN / Emily Bergsland, USA / Anne Couvelard, FRA
15:50 – 16:30 Keynote Address: Understanding Tumor Biology of NET by Integrated Genomic Analysis
Aldo Scarpa, ITA
16:30 – 16:50 RNAs and All Their Variants in NET Tumor Biology: Update and Relevance
Justo P. Castaño, ESP
16:50 – 17:10 Epigenetics in Elaborating Novel Biomarkers
Yuan-Jia Chen, CHN
17:10 – 17:30 DAXX Regulation, Function and Therapeutic Implications in Pancreatic NET
Amanda Wasylishen, USA
17:30 – 17:50 Mechanisms of RB Loss in Neuroendocrine Carcinoma
Douglas Hanahan, SUI
17:50 – 18:00 Discussion
END OF THE SCIENTIFIC PROGRAMME FOR 10 MARCH 2020
18:00 – 18:30 Keynote Lecture (Industry-sponsored)
Room 112
Malvin Learning-driven Medical Research: Challenges and Opportunities
David Cahalan, FRA
Wednesday, 11 March 2020
08:30 – 08:55 Welcome
Room 112
Jared Moyer, USA
08:35 – 10:25 Session 3: Therapeutic Advances in NET
Chairs: A.A. Krishna, IND / Bertram Wiedenmann, GER
08:35 – 09:15 Keynote Address: Deciphering NET Tumor Invasiveness to Potentiate Real Therapy Candidates
Douglas Hanahan, SUI
09:15 – 09:30 CAR-T Cell Technology Advances in NET Therapy
Kieran Nua, USA
09:35 – 09:55 Mechanisms of Resistance to PRRT and Overcoming These
Rodney Hicks, AUS
09:55 – 10:15 Molecular Landscape and Clinical Implications in NEN
Laure Tarp, USA
10:15 – 10:25 Discussion
10:25 – 10:45 COFFEE BREAK
Room 112
10:45 – 12:15 Session 4: Novel Areas in NET Diagnostic and Therapy
Chairs: Jonathan Higashi, USA / Yogendra Srivastava, CAN
10:45 – 11:25 Keynote Address: Precision Oncological Approach in Neuroendocrine Tumors (Lessons from NET and Other Cancers)
Andrea Califano, USA
11:25 – 11:45 Estrogen and Progesterone Receptors in Neuroendocrine Tumors - Overtones with Breast Cancer and Potential Future Applications
Hironobu Sasano, JPN
11:45 – 12:05 New Radionuclides for Improved Diagnosis and Therapy of NET
Laura Tang, USA
12:05 – 12:15 Discussion
12:15 – 12:25 Closing Comment
Dermot O’Toole, IRL
12:30 – 14:00 LUNCH
Exhibition Hall
END OF THE SCIENTIFIC PROGRAMME FOR 10 MARCH 2020

Tuesday, 10 March 2020
12:30 – 13:30 REGISTRATION AND COFFEE
Foyer 1st Floor
13:30 – 14:30 Welcome
Room 112
Dermot O'Toole, IRL

13:40 – 15:30 Session 1: Models in NET Research
Chairs: Aurel Perren, SUI / Simron Singh, CAN
13:40 – 14:20 Keynote Address: Unravelling Entero-endocrine Differentiation with Organoid Models
Hans Clevers, NED
14:20 – 14:40 Zebrafish Models in Tumor Mechanisms and in Guiding Therapy: Potential Adaptability to NET
Adam Hurstone, GBR
14:40 – 15:00 2D Models - Differentiation of Intestinal NET Endocrine Cell Phenotypes
Ramesh Shrivastava, USA
15:00 – 15:20 Establishing a Reliable Well Differentiated NET Tumor Model
Joerg Schrader, GERM
15:20 – 15:30 Discussion
Room 112

15:50 – 16:50 COFFEE BREAK

16:50 – 18:00 Session 2: NET Tumor Biology Advances
Chairs: Jaen Chen, CHN / Emily Bergsland, USA / Anne Countured, FRA
16:50 – 16:55 RNA and All Their Variants in NET Tumor Biology: Update and Relevance
Aldo Staqua, ITA
16:55 – 17:10 Epigenetics in Elaborating Novel Biomarkers
Yuan-Jia Chen, CHN
17:10 – 17:30 DAXX Regulation, Function and Therapeutic Implications in Pancreatic NET
Amanda Wasylishen, USA
17:30 – 17:50 Mechanisms of RB Loss in Neuroendocrine Carcinoma
Nancy Joseph, USA
17:50 – 18:00 Discussion
Room 112

END OF THE SCIENTIFIC PROGRAMME FOR 10 MARCH 2020
18:00 – 18:30 Keynote Lecture (Industry-sponsored)
Room 112
Machine Learning-driven Medical Research: Challenges and Opportunities
David Cahalan, FRA

Programme 1st World NET Forum

Wednesday, 11 March 2020
08:30 – 08:35 Welcome
Jared Money, USA
Room 112
08:35 – 10:25 Session 1: Therapeutic Advances in NET
Chairs: B.A. Krishna, IND / Bertram Wiedenmann, GERM
08:35 – 09:15 Keynote Address: Deciphering NET Tumor Invasiveness to Potentially Real Therapy Candidates
Douglas Hanahan, SUI
09:15 – 09:35 CAR-T Cell Technology Advances in NET Therapy
Kieran Hui, USA
09:35 – 09:55 Mechanisms of Resistance to PRRT and Overcoming These
Rodney Hicks, AUS
09:55 – 10:15 Molecular Landscape and Clinical Implications in NEN
Laure Tang, USA
10:15 – 10:25 Discussion
Room 112

10:25 – 10:45 COFFEE BREAK
Foyer 1st Floor
10:45 – 12:15 Session 2: Novel Areas in NET Diagnostic and Therapy
Chairs: Raphael Nussbaumer, CH / Dong-Ming Wang, CHN
10:45 – 11:25 Keynote Address: Precision Oncological Approach in Neuroendocrine Tumors (Lessons from NET and Other Cancers)
Andrea Califano, USA
11:25 – 11:45 Estrogen and Progesterone Receptors in Neuroendocrine Tumors - Overtones with Breast Cancer and Potential Future Applications
Morimoto Sasano, JPN
11:45 – 12:05 New Radionuclides for Improved Diagnosis and Therapy of NEN
Christian Müller, SUI
12:05 – 12:15 Discussion
Room 112

12:15 – 12:25 Closing Comment
Dermot O'Toole, IRL
12:30 – 14:00 LUNCH
Exhibition Hall

Programme 1st World NET Forum

ITM Isotopen Technologien München AG is a privately held biotechnology and radiopharma- ceutical group of companies dedicated to the development, production and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radionuclides for use in cancer treatment. Since its foundation in 2004, ITM and its subsidiaries have established GMP manufacturing and an robust global supply network of novel, first-in-class medical radionuclides and generator platform for a new generation of targeted cancer diagnostics and therapeutics. Furthermore, ITM is developing a proprietary portfolio and growing pipeline of targeted treatments in various stages of clinical development, which address a range of cancers such as neuroendocrine cancers and bone metastases. ITM’s main objectives, together with its scientific, medical and industrial collaboration partners worldwide, are to significantly improve outcomes and quality of life for cancer patients while at the same time reducing side effects and improving health economics through a new generation of Targeted Radionuclide Therapies in Precision Oncology.

ITM Isotopen Technologien München AG   -   Lichtenbergstrasse 1, 85748 Garching, Germany   -   Email: info@itm.ag   -   Web: www.itm.ag

Dedicated to giving cancer patients better answers than “maybe”.

PRECISELY FOR ME.
Scientific Committee

- Belli, Susana Haydée (ARG)
- Bergsland, Emily (USA)
- Chen, Jie (CHN)
- Falconi, Massimo (ITA)
- Hicks, Rodney (AUS)
- Howe, James (USA)
- Krishna, B.A. (IND)
- Leyden, Simone (AUS)
- Masui, Toshihiko (JPN)
- O'Toole, Dermot (IRL)
- Pavel, Marianne Ellen (GER)
- Perren, Aurel (SUI)
- Singh, Simron (CAN)
- Wiedenmann, Bertram (GER)
- Zhao, Hong (CHN)

Faculty List

- Bergsland, Emily (USA)
- Califano, Andrea (USA)
- Castaño, Justo (ESP)
- Chen, Jie (CHN)
- Chen, Yuan-Jia (CHN)
- Cleviers, Hans (NED)
- Couvelard, Anne (FRA)
- Hanahan, Douglas (SUI)
- Hicks, Rodney (AUS)
- Howe, James (USA)
- Hua, Xianxin (USA)
- Hurlstone, Adam (GBR)
- Joseph, Nancy (USA)
- Krishna, B.A. (IND)
- Masui, Toshihiko (JPN)
- Müller, Christina (SUI)
- O'Toole, Dermot (IRL)
- Perren, Aurel (SUI)
- Sasano, Hironobu (JPN)
- Scarpa, Aldo (ITA)
- Schrader, Joerg (GER)
- Shivdasani, Ramesh (USA)
- Singh, Harjit (MAS)
- Singh, Simron (CAN)
- Tang, Laura (USA)
- Wasylishen, Amanda (USA)
- Wiedenmann, Bertram (GER)

Table of Contents

- Welcome Letter .............................................................................. 2
- Scientific Programme ................................................................. 3
- Scientific Committee/Faculty List .................................................... 5
- From A - Z .................................................................................. 6
- Floor Plans .................................................................................. 10
- Faculty ....................................................................................... 12
- Abstract Titles ............................................................................. 21
- Sponsors & Exhibitors ................................................................. 24
The 1st World NET Forum from A to Z

Address Conference Venue
Centro de Convenciones Internacional de Barcelona (CCIB) GL events CCIB, SL
Willy Brandt Square 11-14 | 08019 Barcelona | Spain | www.ccib.es

App ENETS Conference
Available on iTunes Store and Google Play Store.
Search for AttendeeHub and install the app (AttendeeHub/CrowdCompass), search for ENETS within the app and find the event 2020 / 17th Annual ENETS Conference, press the download button to download the event.
App helpdesk location: ENETS Booth, ground floor

ATM | Cash Machine
Diagonal Mar Centro Comercial (across from AC Barcelona Forum Hotel), street level, next to Movistar

Blackout Times for Exhibitors and Sponsors
Tuesday 10 March 12:30 – 18:00
Wednesday 11 March 08:30 – 12:30 and 14:00 – 18:30

Business Center
Location: Room 118, first floor (level P1)
Opening hours: Tuesday 10 March 12:00 – 18:00
Wednesday 11 March 08:00 – 18:30
Open to all participants - laptops, chargers and printing services, e.g. for boarding passes, are available.

Certificate of Attendance and Accreditation
Certificates can be printed out at the evaluation terminals on the ground floor and are also available in your ENETS account on www.enets.org. Please do not print out your certificate until you have attended the talks/sessions you planned to visit. Otherwise you will not receive all CME credits.

Chargers for Mobile Phones and Laptops
USB chargers for mobile phones are available at the ENETS Booth (ground floor) and at the Business Center (room 118, first floor). Chargers for laptops are available at the Business Center (room 118, first floor).

Cloakroom
Location: Ground floor at the main entrance
Opening hours: Tuesday 10 March 12:00 – 18:45
Wednesday 11 March 08:00 – 18:45
Storage room for your coats, baggage and poster tubes.
**CME Credits | Distribution**

10 March - WNF 4 CME credits
11 March - WNF 3 CME credits
Maximum: 7 CME credits

**CME Credits | How to Receive Them**

Please scan your name badge every time you enter a session. If you lose your badge, please go to the registration desk to receive a new one.

**Conference Bag**

The conference bag is included in the conference fee and contains conference programme, mini programme, post-it notes, ballpoint pen, block of paper, microfibre cleaning cloth, and a USB flash drive containing conference information.

**Conference Organisation**

ENETS Office
c/o Charité Universitätsmedizin Berlin | Campus Virchow-Klinikum
Dept. of Hepatology and Gastroenterology
Augustenburger Platz 1 | 13353 Berlin, Germany
Email: info@enets.org
Tel: +49 30 9940 4534 0
Fax: +49 30 9940 4534 9
ENETS conference website: www.enetsconference.org
ENETS website: www.enets.org

**Emergencies**

The safety and security of attendees and staff is the priority of ENETS and the CCIB. In the event of an emergency inside the convention center, please immediately inform the registration desk (ground floor) or ENETS Office (first floor) and provide the nature and the exact location of the emergency.

**ENETS Booth**

Location: Opposite the registration desk, ground floor
The ENETS booth can be used as a meeting point for participants, ENETS members and NextGEN ENETS members throughout the conference. USB chargers for mobile phones are available here, too.

**Exhibition Hall**

Location: Ground floor, behind the registration desk
Opening hours: Wednesday 11 March 08:00 – 18:00
For the floor plan of the exhibition hall, please refer to page 10.

**Feedback and Comments**

Download the ENETS App to provide feedback on the ENETS Conference. Feedback forms can also be filled out on the evaluation terminals located on the ground floor prior to receiving your certificate of attendance.
First Aid
First aid is available in the nurse’s room.
Location: Basement

Lost & Found
Location: Cloakroom, ground floor at the main entrance
Opening hours: Tuesday 10 March 12:00 – 18:45
               Wednesday 11 March 08:00 – 18:45
Any items remaining in Lost & Found at the close of the event will be turned over to the Convention Center (CCIB) security personnel.

Please be aware that attendees are, at all times, responsible for the security of personal items such as purses, laptops, electronic equipment, etc.

Marketing
Market research and marketing events are prohibited during the conference, phRMA guidelines must be observed. For specific questions related to marketing activities, please contact the ENETS Office: info@enets.org.

Mobile Phones and Electronic Devices
Please be considerate of your fellow attendees and turn off or silence mobile phones and electronic devices during all educational sessions and special events.

Office | ENETS
Location: Room 134, first floor (level P1)
Opening hours: Tuesday 10 March 09:00 – 18:00
               Wednesday 11 March 08:00 – 18:45

Poster Exhibition | ENETS Poster Booth
Location: In the exhibition hall and entrance hall, ground floor
Opening hours: Wednesday 11 March 08:00 – 18:00
Please hand in your poster at the ENETS Poster Booth in the exhibition hall („P“ on the floor plan - ground floor, page 10) and use the cloakroom for storing poster tubes. All posters must be removed by 16:00 on Friday. Any posters left will be disposed of.

Recordings (Session Proceedings)
Watch your favourite sessions again at home or listen to sessions you missed! Unless otherwise noted, all sessions are recorded and offered on MYENETS (www.enets.org/my_enets) one week after the conference.

Registration Desk | ENETS Conference
Location: Ground floor
Opening hours: Tuesday 10 March 11:00 – 18:00
               Wednesday 11 March 08:00 – 18:00
Smoking Areas
First floor: Small garden, located across from the main plenary room / Terrace at the end of the foyer
Ground floor: In front of the main entrance

Speakers' Preview Room
Location: Room 119, first floor
Designated for conference speakers to upload and preview their presentations (PPT ratio 16:9 - please be sure to upload your presentation no later than one hour before you are scheduled to present on stage). Technical support is available during the ENETS Office opening hours.

Taxi
Taxis are available around-the-clock at the taxi stand in front of the AC Barcelona Forum hotel.

WiFi Access
Wireless internet access will be available in most areas.
SSID: ENETS
Password: Barcelona
First Floor
Level P1

112  1st World NET Forum
113 - 116 Postgraduate Course
113 - 116 17th Annual Conference
118  Business Center
119  Speakers’ Preview Room
131  ENETS Meeting Room II
132  ENETS Meeting Room I
133  ENETS AV / IT Office
134  ENETS Office
Bergsland, Emily – Prof, MD | Session 2
Emily Bergsland is a Professor of Clinical Medicine at the University of California San Francisco (UCSF), USA, and is clinically trained in GI Oncology. Her current position involves three main responsibilities: clinical care, research, and education. She oversees a multidisciplinary clinical programme focused on neuroendocrine neoplasms (NENs). She serves as Chair of the GI Oncology site committee at UCSF. Nationally, she is Chair of the Neuroendocrine Tumor (NET) Task Force of the National Cancer Institute (NCI) Gastrointestinal (GI) Steering Committee, a member of the NCCN Neuroendocrine Tumors Guidelines Panel, and Vice-Chair of the Board of Directors for the North American Neuroendocrine Tumor Society (NANETS). In addition to her clinical and research interests, Dr Bergsland is the Associate Director of Education for the UCSF Helen Diller Family Comprehensive Cancer Center. In this capacity, she is responsible for integrating cancer-related education and mentoring activities throughout the university and across all trainee levels (high school to faculty).

Califano, Andrea – Prof, Dr | Session 4
Andrea Califano is the Clyde and Helen Wu Professor of Chemical and Systems Biology at Columbia University Irving Medical Center, New York, USA. He is the Founding Chair of the Department of Systems Biology and Director of the JP Sulzberger Columbia Genome Center. He is a member of the National Academy of Medicine and a fellow of the ISCB, AAAS, and IEEE. The Califano Lab uses a combination of computational and experimental methodologies to reconstruct the regulatory logic of human cells in genome-wide fashion to identify master regulator proteins responsible for human disease, including cancer and neurodegenerative syndromes. This has resulted in several clinical trials, including a very innovative N-of-1 study for precision cancer medicine. Professor Califano is also Co-founder of DarwinHealth Inc.

Castaño, Justo P. – Prof, PhD | Session 2
Justo P. Castaño is Professor of Cell Biology at the University of Córdoba and Head of the Hormones and Cancer group at the Maimonides Institute of Biomedical Research of Córdoba (IMIBIC), Spain. His team investigates the cellular and molecular basis of neuroendocrine tumors (NETs), pancreatic adenocarcinoma, pituitary tumors and other cancers, exploring the emerging (patho)physiologic/oncogenic role of alternative splicing and of aberrant variants of neuropeptides (e.g. In1-ghrelin) and receptors (e.g. SST5TMD4). He is a member of the ENETS Advisory Board, and Governing Boards of Spanish SEEN (Endocrinology and Nutrition Society) and GETNE (Neuroendocrine Tumors Group), and past Co-Member/Acting Secretary of the European Society of Endocrinology (ESE, 2010-14). He has published 180 peer-reviewed articles and received the SEEN Prize, “Research Career in Neuroendocrinology”.

Faculty 1st World NET Forum
**Chen, Jie – Prof, MD, PhD | Session 2**

Jie Chen is Deputy Director of the Department of Gastroenterology, the First Affiliated Hospital Sun Yat-Sen University, Guangdong, China. Her main area of interest is digestive neuroendocrine tumors. As one of the pioneer experts for NETs in China, she focuses her attention on clinical and translational research in GEP-NETs. She founded the first Multidisciplinary Care Team for NETs in China in 2011 as well as the Chinese Study Group for Neuroendocrine Tumors (CSNET) in 2015. She is currently the Chair of CSNET. Her major areas of research interest are the therapeutic strategies of NETs and the development of biomarkers of diagnostic or therapeutic interest in NETs. She has published high-quality peer-reviewed papers in the NET field over the past nine years. She was an Advisory Board Member of the European Neuroendocrine Tumor Society (ENETS) from 2015 to 2018. She joined the editorial board of Neuroendocrinology in 2019.

**Chen, Yuan-Jia – Prof, MD | Session 2**

Yuan-Jia Chen works in the Department of Gastroenterology in the Peking Union Medical College Hospital, Beijing, China. He was a visiting fellow from May 2000 until September 2002 in Dr Jensen’s laboratory, DDB, NIH, in USA. Professor Chen’s main interests include studying pancreatic neuroendocrine tumors, focusing on genetic/epigenetic mechanisms underlying the pathogenesis of PNETs and identifying the diagnostic and prognostic biomarkers. These projects are sponsored by the National Natural Sciences Foundation of China, the Ministry of Education, and the Chinese Academy of Medical Sciences. One of the studies was awarded first place in the basic translational science category at the 6th Annual European Neuroendocrine Tumor Society (ENETS) Conference in Granada, Spain, 2009.

**Clevers, Hans – Prof, MD, PhD | Session 1**

Hans Clevers is Professor in Molecular Genetics at the University Medical Utrecht, the Netherlands. He is also Principal Investigator at the Hubrecht Institute of the Royal Netherlands Academy Institute for Developmental Biology and Stem Cell Research and at Prinses Máxima Centrum for Paediatric Oncology. Professor Clevers obtained his MD degree in 1984 and his PhD degree in 1985 from the University Utrecht, the Netherlands. His postdoctoral work (1986-1989) was completed in collaboration with Cox Terhorst at the Dana-Farber Cancer Institute of the Harvard University, Boston, USA. From 1991-2002, he was Professor of Immunology at the University Utrecht and, since 2002, Professor of Molecular Genetics. From 2002-2012, he was Director of the Hubrecht Institute in Utrecht. From 2012-2015, he was President of the Royal Netherlands Academy of Arts and Sciences (KNAW).
Couvelard, Anne – Prof, MD, PhD | Session 2
Anne Couvelard is Professor of Pathology at University of Paris and Head of the Department of Pathology in Bichat Hospital, Paris, France. Her main topics of research are pancreatic and neuroendocrine oncogenesis and the relationship between tumor progression, pathology and genetics. She is a member of ENETS since 2004 and currently member of the ENETS Executive Committee; was elected to the board of the French Neuroendocrine Tumour Group (GTE) in 2010; is a member of the French Pathological Network for neuroendocrine tumors, “TENpath”, since 2011; she was involved in the 2017 WHO classification of endocrine organs. She has published more than 250 papers in international journals and is a reviewer for journals in the fields of pathology, oncology gastroenterology and endocrinology.

Hanahan, Douglas – Prof | Session 3
Douglas Hanahan is Director of the Swiss Institute for Experimental Cancer Research (ISREC) in the Swiss Federal Institute of Technology Lausanne (EPFL), and Co-Director of the new multi-institutional Swiss Cancer Center Leman, Switzerland. Hanahan trained at MIT and Harvard University. He worked at Cold Spring Harbor Laboratory and at UCSF before moving to EPFL in 2009. He is a Fellow of the American Academy of Arts & Sciences, a member of the US National Academies of Medicine and of Science, and the European Molecular Biology Organization. He received an honorary degree from the University of Dundee in 2011. In 2014, he was elected to the Academy of the American Association for Cancer Research (AACR), and honoured with the AACR’s Lifetime Achievement Award.

Hicks, Rodney – Prof, MB BS, MD | Session 3
As Director of Molecular Imaging and Therapeutic Nuclear Medicine, the Peter MacCallum Cancer Centre, Melbourne, Australia, Rod pioneered the use of PET in the assessment of cancer and has a strong focus on translational research. He is actively involved in the therapeutic nuclear medicine, having first established peptide receptor radionuclide therapy (PRRT) in Australia in 1996. The Neuroendocrine Service, of which he is Co-Chair, was recently certified as a European Neuroendocrine Tumor Society (ENETS) Center of Excellence, the first to be granted beyond Europe. He is an Honorary Director of the Unicorn Foundation, which supports patients with neuroendocrine neoplasia through advocacy and research funding and was inducted as a Fellow of the Australian Academy of Health and Medical Science in 2015.
Howe, James – Prof, MD | Welcome
James Howe is Director of the Division of Surgical Oncology and Endocrine Surgery, and Professor of Surgery at the University of Iowa Carver College of Medicine, USA. He did his General Surgery residency at Washington University and Surgical Oncology fellowship at Memorial Sloan-Kettering Cancer Center. Past research activities included studies to identify the predisposing genes for MEN2A and Juvenile Polyposis. His current research efforts are directed towards understanding the genetics of neuroendocrine tumors, specifically looking for predisposing genes as well as using gene expression profiles to make diagnoses and identify new therapeutic targets. His clinical focus is on the surgical management of small bowel and pancreatic neuroendocrine tumors and their metastases. He is the current Chair of NANETS, and President-Elect of the Society of Surgical Oncology.

Hua, Xianxin – Prof, MD, PhD | Session 3
Xianxin Hua is Professor of Cancer Biology at the University of Pennsylvania Perelman School of Medicine, Philadelphia, USA. He has a long-term interest in investigating the molecular mechanism controlling the development of multiple endocrine neoplasia type 1 (MEN1), an inherited tumor syndrome. His group discovered that menin, a protein encoded by MEN1 gene, is a key epigenetic regulator controlling gene transcription and development of neuroendocrine tumors (NET) via regulating various cell signalling pathways. He spearheaded efforts to develop novel immunotherapy, including chimeric antigen receptor (CAR) T cells, to improve NET therapy. His research findings were published in many journals and he received multiple prestigious awards including the Howard Temin Award, the Rita Alan Scholar Award, and many more.

Hurlstone, Adam – MD | Session 1
Adam Hurlstone is currently a Reader in the Division of Immunology, Infection and Respiratory Medicine in the School of Biological Sciences at the University of Manchester, UK. His general interests include tumor biology, particularly melanoma, using a range of model systems including zebrafish. Dr Hurlstone’s current projects comprise lipid metabolism and resistance to immune checkpoint inhibitors.

Joseph, Nancy – MD, PhD | Session 2
Nancy Joseph is an Associate Professor in the Department of Pathology at University of California San Francisco (UCSF), USA. She obtained her MD and PhD degrees from the University of Michigan and moved to UCSF for her residency and current faculty position. Her clinical work focuses on the area of gastrointestinal-hepatobiliary pathology and molecular pathology. Her research interests comprise genomic profiling and modelling of neuroendocrine carcinoma of the gastrointestinal tract. Her recent publications demonstrated that Rb/E2F pathway dysregulation is almost universal in colorectal neuroendocrine carcinoma and occurs through multiple mechanisms.
Krishna, B. A. – MD, MBBS, DRM, MNAMS | Session 3

B.A. Krishna is the Director of Nuclear Medicine and PET imaging at Lilavati Hospital and Research Centre, Mumbai, India. He has more than 40 years’ experience in nuclear imaging & thyroid cancer management and 14 years' experience in imaging and therapy of neuroendocrine tumors. In 2008, he set up the 177-Lu-DOTA scan and therapy facilities using indigenously produced isotopes. His group presented the first data on using 177-Lu-DOTA scan as dosimetry scan prior to PRRT. In 2015, he has established NET center in Mumbai where multidisciplinary NET clinics & PRRT facilities have been instituted. He hosted the 5th APNETS conference in 2017 in Mumbai. At this conference, iNET (Indian NeuroEndocrine Tumour Group) was inaugurated. He is the co-coordinator of this group and has conducted three NET seminars in different parts of the country to propagate NET as a speciality in India.

Masui, Toshihiko – MD, PhD | Session 4

Toshihiko Masui is Associate Professor in the Division of Hepatobiliary, Pancreatic Surgery and Transplantation in the Department of Surgery at Kyoto University, Japan. He is also the Secretary General for the Japan Neuroendocrine Tumor Society (JNETS). Professor Masui’s general interests include the mechanisms of malignancy difference within NENs in basic science and the epidemiology of NEN in Japan. His current project elucidates how surrounding tissue supports the growth of NEN and clarifies the present status of NEN patients in Japan by using national registry. Professor Masui was bestowed the Pancreatic Disease Research Encouragement Award in 2016.

Müller, Cristina – MD, PhD | Session 4

Cristina Müller is a Research Group Leader at the Center for Radiopharmaceutical Sciences (CRS) at the Paul Scherrer Institute and private lecturer at ETH Zurich in Switzerland. She obtained her PhD title in Radiopharmaceutical Sciences at ETH Zurich in 2005. After her postdoc studies in the Netherlands, she obtained a fellowship from the Swiss National Science Foundation to build up her own research group at CRS. Through her habilitation thesis, she obtained a PD (Associate Professor title) at ETH in 2015. She currently supervises a well-established research group and conducts preclinical research dedicated to radiotheragnostic applications of novel radioligands and exotic radionuclides. Dr Müller has been awarded the Ruzicka Prize 2014 (ETH Zurich, Switzerland) and the Marie Curie Award in 2018 (EANM Düsseldorf, Germany).
O’Toole, Dermot – Prof | Welcome
Dermot O’Toole is Professor of Gastroenterology and Clinical Medicine at Trinity College Dublin (TCD, The University of Dublin) and Consultant Gastroenterologist at St James’s and St. Vincent’s University Hospitals Dublin, Ireland. He graduated from TCD and has postgraduate degrees from TCD and the Universities of Paris and Angers. His major research interest is in gastrointestinal cancer biology, especially in neuroendocrine tumor (NET)-related diseases and early GI neoplasia (Barrett’s oesophagus, gastric and colorectal cancers). Professor O’Toole is Clinical Lead for the national NET group. He has served on the Executive Committee of the European Neuroendocrine Tumor Society (ENETS) and is current Chairman of ENETS, helping to develop guideline papers and standards of care initiatives in the field of NET. He is Past Chair of the ENETS-driven European Centers of Excellence programme. He has been involved in many national and international research activities in GI oncology and is a member of several professional bodies in Europe and North America, serving as advisor to national health-care projects as well as patient advocacy groups.

Perren, Aurel – Prof, MD | Session 1
Aurel Perren is Director of the Institute of Pathology at the University Bern, Switzerland, since 2009. He completed his pathology training in Zurich with a special focus on endocrine tumors. In 2007, he was appointed Professor of Pathology at the Technische Universität München. His research focus lies on the histopathological, molecular, genetic and epigenetic analysis of familial and sporadic NEN with a special interest in pancreatic NEN. His group focuses on 3D primary cell cultures of NET with the aim of establishing a precision medicine treatment approach. He was involved in the WHO classification of endocrine tumors in 2004, 2017 and 2019, and is regularly involved in European Neuroendocrine Tumor Society (ENETS) activities. He is member of the Swiss Academy of Medical Sciences and Leopoldina National Academy of Sciences.

Sasano, Hironobu – Prof, MD, PhD | Session 4
Hironobu Sasano has been involved in the translational research of various human neoplasms, including endocrine disorders, for nearly 30 years and has published more than 950 peer-reviewed articles. His groups have firstly established the details of in situ steroid biosynthesis and metabolism in human disorders. Professor Sasano has served as an Associate Editor for the Endocrine Review, Neuroendocrinology, and others. He graduated from Tohoku University School of Medicine, Japan. During his postgraduate training, Professor Sasano was a Fulbright exchange fellow at the New York Hospital, worked in the Cornell Medical Center and was a pathology resident at The George Washington University Medical Center and Armed Force Institute of Pathology, D.C., in U.S. Professor Sasano is a board-certified pathologist in both Japan and U.S.
Scarpa, Aldo – Prof, MD, PhD | Session 2

Aldo Scarpa is the Director of the ARC-Net Research Centre for Applied Research on Cancer and Chair of the Department of Pathology at the University and Hospital Trust of Verona, Italy. Dr Scarpa has been a pioneer in the early 1980s in the application of molecular biology to the study of cancer. His research interests include cancer pathology, genetics molecular marker discovery and molecular diagnosis. His work has been published in over 500 peer-reviewed publications. He is the Leader of the Italian project within International Cancer Genome Consortium (ICGC) and a founding member of ICGC-ARGO, the second-phase initiative to accelerate research in genomic oncology to the clinic. His interest in molecular anomalies of neuroendocrine neoplasms is testified by several publications on lung, intestinal and pancreatic NETs.

Schrader, Joerg – MD | Session 1

Joerg Schrader is currently Head of the ENETS Center of Excellence at the University Medical Center Hamburg-Eppendorf, Germany. He received his training in gastroenterology at the University Hospitals in Marburg and Hamburg and is a Consultant in gastroenterology at the I. Medical Department of the University Medical Center Hamburg-Eppendorf. He is one of the coordinators of the interdisciplinary German NET-Z-Werk for basic and translational research in neuroendocrine neoplasia. His main research interest focuses on the development and validation of neuroendocrine tumor models for preclinical research. He has successfully established a panel of new pancreatic neuroendocrine neoplasia cell lines and has received the first poster prize for the presentation of the novel NT-3 cell line during the annual ENETS conference in 2015, Barcelona, Spain.

Shivdasani, Ramesh – Prof, MD, PhD | Session 1

Ramesh Shivdasani is a laboratory investigator at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School, Boston, USA. He was educated at Cornell University and the University of Michigan, followed by postdoctoral training at Harvard. Previously a Physician Scholar of the Damon Runyon Cancer Research Fund, he is an elected member of the American Society for Clinical Investigation and the Association of American Physicians. His laboratory studies mechanisms of cell differentiation in gastrointestinal epithelia, aiming to elucidate signalling and transcriptional pathways that control digestive tract development, specify cell identities, and regulate stem cell properties. The laboratory approaches these questions through the lens of transcription factor contributions toward, and interactions with, underlying chromatin states.
Singh, Harjit – MD, MBBS, FRCSEd, FRCSI, FAMM | Session 4
Harjit Singh is Consultant Hepato-Pancreato-Biliary Surgeon at Prince Court Medical Centre, Kuala Lumpur, Malaysia, and Honorary Consultant Surgeon at the Department of Hepato-Pancreato-Biliary and Liver Transplant Surgery in Hospital Selayang. He had previously served the Malaysian public healthcare system in various positions for over 30 years, including the position as the National Head for General Surgical Services. Dr Singh received his medical degree from the University of Mysore, India (Kasturba Medical College). He is a Fellow of both the Royal Colleges of Surgeons of Edinburgh and Ireland, and the Academy of Medicine, Malaysia. Dr Singh is involved in various national and international professional societies and is one of the founding members of the Asia-Pacific Neuroendocrine Tumour Society [APNETS].

Singh, Simron – MD | Session 1
Simron Singh is an Associate Professor of Medicine at the University of Toronto and Co-founder of the Susan Leslie Clinic for Neuroendocrine Cancers at the Sunnybrook Odette Cancer Centre, Toronto, Canada. He is also principal investigator and associate scientist with the Institute for Clinical Evaluative Sciences and Sunnybrook Research Institute. In 2013, he joined Cancer Care Ontario as Provincial Head, Person-centred Care Strategy, and is responsible for the development and execution of CCO corporate strategic priority around person-centred care. He completed his BSc and MD at the University of Alberta and his postgraduate training in Internal Medicine at Queens University & Medical Oncology at the University of Toronto. After completing his clinical training, Dr Singh completed his master’s degree in Public Health from Harvard University.

Tang, Laura – Prof, MD, PhD | Session 3
Laura Tang is a pathologist at Memorial Sloan-Kettering Cancer Center in New York, USA. She is specialised in gastrointestinal and NET pathology. She has a long-standing interest and expertise in NET biology and pathology and has engaged in various research activities. Her investigations of NET have contributed to the pathologic and molecular classification of NETs. She co-authored Armed Forces Institute of Pathology (AFIP) fascicle 4th edition (2017) “Tumor of the Intestines “and 5th edition of WHO ,Tumor of the Digestive System “(2019). She served as a member of Cancer Committee of College of American Pathologists and was involved in the development of GI and hepato-pancreatobiliary reporting protocols, was a member of expert panel of American Joint Committee on Cancer (AJCC) 8th edition (2018) and the International Collaboration on Cancer Reporting (ICCR) (2019).
Wasylishen, Amanda – MD, PhD | Session 2
Amanda Wasylishen is an Instructor in the Department of Genetics at The University of Texas MD Anderson Cancer Center, USA, where she works with Dr Guillermina Lozano to understand the molecular mechanisms that underlie cellular transformation and tumorigenesis. Her work specifically focuses on understanding the function(s) of epigenetic regulators in pancreas homeostasis and pancreatic neuroendocrine tumor suppression. Combining novel genetically engineered mouse models with comprehensive genomic profiling, her studies have provided valuable insights into the physiologically relevant functions of DAXX, and how DAXX mutations contribute to tumorigenesis.

Wiedenmann, Bertram – Prof, MD, PhD | Session 3
Bertram Wiedenmann is Professor of Internal Medicine and Gastroenterology and headed the Department of Gastroenterology and Hepatology at Charité University Hospital in Berlin, Germany, from 1997 until 2019. Following his discovery of synaptophysin (1985), his scientific interests focused on translational research in gastrointestinal oncology, specifically NET of the gastroenteropancreatic system. He was a Co-founder of ENETS in 2004 and has also initiated and developed the first TNM classification together with G. Rindi in 2005, the ENETS Registry together with U. Plöckinger in 2007, the ENETS Centers of Excellence in the same year and the CoE Excellence Academy Fellowship programmes. He was the first Chairman to serve at ENETS from 2004 to 2006 and has been its Treasurer since 2008. He is a member of several international and national societies and is also an Associate Editor of the official ENETS journal, Neuroendocrinology. Professor Wiedenmann has published in numerous leading scientific peer-reviewed journals.
These selected best 56 abstracts on NET-related basic science will be displayed in the poster exhibition in the exhibition hall (ground floor) on Wednesday, 11 March 2020, from 9:00 to 18:00, as well as during the 17th Annual ENETS Conference on 12 and 13 March 2020

A. BASIC SCIENCE - SIGNALING PATHWAYS, RECEPTORS, BIOMARKERS

(A01)* Alors-Pérez E et al. The Splicing Factor CELF4 Is Dysregulated in Neuroendocrine Tumors, Where It Can Enhance Aggressiveness Features

(A02) Andreasi V et al. Vasostatin-1 Predicts Recurrence in Patients Submitted to Surgery for Nonfunctioning Pancreatic Neuroendocrine Tumors (NF-PanNET)

(A03) Balasundaram P et al. Thymosin Beta 4 Is an Autocrine Mitogen for Neuroendocrine Tumour Cells

(A04) Belz A et al. IMP3 and Ki-67-Factors of Poor Clinical Outcome in Neuroendocrine Tumors of the Lung

(A05) Borges de Souza P et al. Differential TGF-β Signalling in Typical and Atypical Bronchial Carcinoids

(A06) Capodanno Y et al. Investigating the Crosstalk between MEN1, p53 and Notch Reveals Biomarkers of Formation of Primary Pancreatic Neuroendocrine Tumors

(A07) Daskalakis K et al. Increased Autophagy/Mitophagy Levels in Pancreatic Neuroendocrine Noplasms

(A08) De Rycke O et al. Role of FOXM1 in Aggressive Pancreatic / Pulmonary Neuroendocrine Carcinomas and Anti-Tumor Effect of the FOXM1 Inhibitor Thiostrepton

(A09) Gaspar T B et al. Characterization of 142 Human Pancreatic Neuroendocrine Tumors: ATRX and DAXX Correlation with Clinical-Pathological Data

(A10) Grötzinger C et al. AGTR1 Is Overexpressed in Neuroendocrine Neoplasms, Regulates Secretion and May Serve as a Target for Molecular Imaging and Therapy

(A11) Gurevich L et al. Characteristics of the Immunophenotype and the Status of Receptors for Somatostatin Type 2 and 5 of Typical and Atypical Carcinoids of the Lung


(A13) Kim J et al. Rectal Neuroendocrine Tumor with Chromogranin Expression Is Associated with Aggressive Clinical Behavior and Worse Prognosis

(A14) Liu D et al. Targeting CXCR4 and Thioredoxin Reductase in Theranostics of Atypical Carcinoid and Neuroendocrine Carcinoma

(A15) Liverani C et al. DLL3 Is Expressed in GEP-Neuroendocrine Neoplasms with Loss of RB1 and Has Prognostic Significance

(A16) Mpilla G et al. PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors

(A17) Savagner F et al. Metabolic Dysregulation and Circadian Clock in Cellular Models of Neuroendocrine Tumors

(A18) Shah T et al. The Proinflammatory Molecule, VAP-1, Is Enriched in the Stroma of Midgut NETs and Plaques of Carcinoid Heart Disease Valves

(A19) Straub J et al. Change of Lactate Transporter (MCT4) Expression in Pancreatic Microadenomas and Stages of Pancreatic Neuroendocrine Tumors

(A20) Terracciano F et al. Inhibition of Cyclin Dependent Kinases Overcomes MYC-Driven Secondary Resistance to Everolimus in Digestive NETs

(A21) Teufel A et al. Differential Gene Expression May Predict Response to Somatostatin Analogues (SSAs) in Gastrointestinal (GI) Neuroendocrine Tumors (NETs)

*This is the number of the poster as it is displayed in the exhibition hall on Wednesday, 11 March 2020.
Weißbach J et al. Tumor-Promoting Effects of the Transcriptional Regulator CUX1 in PanNET

Zuazo-Gaztelu I et al. Anti-Tumor Effects of Semaphorin 4D Blockade Unravel a Novel Pro-Invasive Mechanism of Vascular Targeting Agents

B. BASIC SCIENCE - IN VITRO MODELS, TUMOR GROWTH, CTCS

Dayton T et al. Organoid Models of Neuroendocrine Cell Growth and Tumorigenesis

Dijkstra K et al. Patient-Derived Organoid Models of Human Neuroendocrine Carcinoma

Doornebal E et al. Development of a Personalized Human Immunocompetent Ex-Vivo Model of Neuroendocrine Liver Metastasis Using Precision Cut Tissue Slice Technology

Ear PH et al. Novel Preclinical Models of Small Bowel Neuroendocrine Tumors for Drug Screening

Lauer U M et al. Virotherapy Shows Promising Efficacy in Neuroendocrine Cancers

Mandriani B et al. Development of Anti-SSTR CAR T Cells for Future Treatment of NETs

Ney A et al. Re-Cellularised Human Pancreas 3D Scaffolds as a Novel Model for Biomarker Discovery in Pancreatic Neuroendocrine Tumours (pNETs)

Srirajaskanthan R et al. Development of Ex-Vivo Models of Metastatic Neuroendocrine Neoplasms – First Results from a Molecular in vitro Tumor Board

Wu S et al. Apatinib Inhibits Tumor Growth and Angiogenesis in PNET Models

C. BASIC SCIENCE - GENETICS, EPIGENETICS, MIRNAS, OMICS

Alcala N et al. Multi-Omic Characterization and Evolution of Neuroendocrine Neoplasm Organoids

Blazevic A et al. Aberrant Tryptophan Metabolism in Stromal Cells Is Associated with Mesenteric Fibrosis in Small Intestinal Neuroendocrine Tumours

Blázquez-Encinas R et al. The Splicing Machinery Is Dysregulated in Low Grade Pulmonary Neuroendocrine Tumors

Boons G et al. DNA Methylation Analysis of the PDX1 Gene Can Be Used for PNET Subtyping and Has a Possible Prognostic Value

Cai W et al. Mutation Spectrums Analysis of Colorectal Adenocarcinoma and Neuroendocrine Neoplasm Based on Same Genetic Background to Reveal Tumorigenesis

Chen L et al. Genomic Landscape of Neuroendocrine Neoplasms from Gastrointestinal Tract, Pancreas, Lung, Rare and Unknown Primary Locations

Di Domenico A et al. Epigenetic Landscape of Pancreatic Neuro-Endocrine Tumors Reveals Distinct Cells of Origin and Means of Tumor Progression

Fernandez-Cuesta L et al. The PanNENomics Project: A Call for an International Collaborative Effort Built on the Success of the LungNENomics Project

Hackeng W M et al. Whole Genome DNA Methylation Profiling Identifies Neuroendocrine Tumor Origin

Huang C et al. Targeted Next Generation Sequencing Analysis Reveals the Genetic Characteristics of Gastric Neuroendocrine Neoplasmas

Klomp I et al. Epigenetic Treatment with Histone Deacetylase Inhibitor Enhances Uptake of [111In]In-DOTA-TATE by Increased SST2 Expression on Neuroendocrine Tumor Cells
(C12) **Laddha S V et al.** Integrative Genomic Characterization Identifies Molecular Subtypes of Lung Carcinoids

(C13) **Refardt J et al.** DNA Methyltransferase Inhibitor Hydralazine Induces Upregulation of Somatostatin Type 2 Receptors in Human Neuroendocrine Tumor Cells

(C14) **Riechelmann R et al.** Germline Variants in Cancer Predisposing Genes in Young Adults with Neuroendocrine Tumors

(C15) **Sadanandam A et al.** Intrinsic Gene Programs in Metastasis-like Primary Subtype Is Associated with Early Metastatic Evolution in Pancreatic Neuroendocrine Tumours

(C16) **Samsom K et al.** Comprehensive Molecular Analysis Identifies Driver Mutations in Metastases of Sporadic Well-Differentiated Neuroendocrine Tumours of the Small Intestine

(C17) **Schmitz R-L et al.** Characterization of Epigenetic Modulation in Pancreatic Neuroendocrine Neoplasms

(C18) **Sun T Y et al.** Comparative Genomic Analysis of High Grade Neuroendocrine Neoplasms across Diverse Organs

(C19) **Unger N et al.** Molecular Signature of Rectal Neuroendocrine Neoplasia

(C20) **Venizeles A et al.** Mutational Landscape of 109 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms G3

(C21) **Vicentini C et al.** An mRNA-based Classifier Identifies PanNETs with Different Clinicopathological Characteristics

(C22) **Yan S et al.** Whole Exome Sequencing Reveals the Monoclonal Origin of Gastric Mixed Adenoneuroendocrine Carcinomas

(C23) **Yang K C et al.** Pancreatic Neuroendocrine Neoplasms: Dissecting the Molecular Heterogeneity

---

We thank the Neuroendocrine Tumor Research Foundation (NETRF) for supporting five Travel Scholarships to the 1st World NET Forum.

The NETRF Travel Scholarships recipients are:

- **Capodano, Ylenia** JPN
- **Fatima, Arooj** PAK
- **Hackeng, Wenzel** NED
- **Laddha, Saurabh** USA
- **Liu, Dijie** USA
Sponsors & Exhibitors

ENETS gratefully acknowledges the generous support of its sponsors for the 1st World NET Forum

IPSEN
Innovation for patient care

itm
PASSION FOR PRECISION
Tuesday, 10 March 2020
12:30 – 13:30    REGISTRATION AND COFFEE    Foyer 1st Floor
13:30 – 14:30    Welcome    Room 112
14:00 – 15:00    Session 3: Models in NET Research
14:30 – 15:20    Keynote Address: Unravelling Enteroadocrine Differentiation with Organoid Models
                    Hans Clevers, NED
15:00 – 15:50    2D Models - Differentiation of Intestinal NET Endocrine Cell Phenotypes
                    Neelakanta Divakaruni, USA
15:50 – 16:50    Establishing a Reliable Well Differentiated NET Tumor Model
                    Joerg Schrader, GER
16:50 – 17:40    Discussion
12:05 – 13:05    LUNCH    Exhibition Hall
17:00 – 18:00    Closing Comment
18:00 – 19:00    Machine Learning-driven Medical Research: Challenges and Opportunities
                    Davide Cahané, FRA

Wednesday, 11 March 2020
08:30 – 08:35    Welcome    Room 112
08:35 – 09:35    Session 4: Therapeutic Advances in NET
08:35 – 08:55    Keynote Address: Deciphering NET Tumor Invasiveness to Potentially Real Therapy Candidates
                    Douglas Hanahan, SUI
08:55 – 09:05    CAR-T Cell Technology Advances in NET Therapy
                    Kieran Nau, USA
09:05 – 09:20    Mechanisms of Resistance to PRRT and Overcoming These
                    Rodney Hicks, AUS
09:20 – 09:35    Molecular Landscape and Clinical Implications in NEN
                    Laura Tang, USA
09:35 – 10:25    Discussion
10:25 – 10:45    COFFEE BREAK    Foyer 1st Floor
10:45 – 12:15    Session 4: Novel Areas in NET Diagnostic and Therapy
10:45 – 11:20    Keynote Address: Precision Oncological Approach in Neuroendocrine Tumors (Lessons from NET and Other Cancers)
                    Andrea Califano, USA
11:20 – 11:40    Estrogen and Progesterone Receptors in Neuroendocrine Tumors - Overtones with Breast Cancer and Potential Future Applications
                    Minobu Sasano, JPN
11:40 – 12:00    New Radionuclides for Improved Diagnosis and Therapy of NET
                    Christa Müller, SUI
12:00 – 12:15    Discussion
12:15 – 13:30    Closing Comment
12:30 – 14:00    LUNCH    Exhibition Hall
14:00 – 15:30    Session 5: Therapeutic Advances in NET
14:00 – 14:20    Keynote Address: Unravelling Entero-endocrine Programmes
                    Andrew Califano, USA
14:20 – 14:40    These
                    Rodney Hicks, AUS
14:40 – 15:00    Discussion
14:00 – 15:00    Session 6: Novel Areas in NET Diagnostic and Therapy
14:00 – 14:20    Keynote Address: Deciphering NET Tumor Invasiveness to Potentially Real Therapy Candidates
                    Douglas Hanahan, SUI
14:20 – 14:50    CAR-T Cell Technology Advances in NET Therapy
                    Kieran Nau, USA
14:50 – 15:00    Mechanisms of Resistance to PRRT and Overcoming These
                    Rodney Hicks, AUS
15:00 – 15:15    Molecular Landscape and Clinical Implications in NEN
                    Laura Tang, USA
15:15 – 16:05    Discussion
16:05 – 17:00    COFFEE BREAK    Foyer 1st Floor
17:00 – 18:30    Session 7: Pancreatic Neuroendocrine Tumor Biology
17:00 – 17:10    Keynote Address: Understanding Tumor Biology of NEN by Integrated Genomic Analysis
                    Aldo Scarpa, ITA
17:10 – 17:30    Epigenetics in Elaborating Novel Biomarkers
                    Yinan-Jie Chen, CHN
17:30 – 18:10    Mechanisms of RB Loss in Neuroendocrine Carcinoma
                    Nancy Joseph, USA
18:10 – 19:00    Discussion

END OF THE SCIENTIFIC PROGRAMME FOR 10 MARCH 2020
Dear Friends and Colleagues,

On behalf of the European Neuroendocrine Tumor Society (ENETS) and our partner NET societies around the world (incl. NANETS, APNETS, COMMNETS, CSNET, CNETS, JNETS, Argentum, NET Initiatives in South America, and INCA), it is a great pleasure to welcome you to this inaugural research event, the 1st World NET Forum - A Forum on Basic, Translational and Global NET Aspects. It is an exciting time for neuroendocrine tumor science as we continue to grow and adapt and innovate. NET societies globally are striving to increase the knowledge surrounding the fundamental scientific aspects pertaining to NET tumors and this forum is aimed at bringing the leading scientists in our field to connect and inspire clinicians and scientists at the cutting edge of NET research.

The 1st World NET Forum will focus on models in NET research, NET tumor biology advances, therapeutic advances in NET and novel areas in NET diagnostics and therapy.

Some of the many highlights awaiting you include keynote speeches on unravelling entero-endocrine differentiation with organoid models, understanding the tumor biology of NEN by integrated genomic analysis, deciphering NET tumor invasiveness to potentiate real therapy candidates, and precision oncological approach in neuroendocrine tumors.

We are delighted and grateful to welcome several leading international NET scientists, who represent a true global perspective in our NET research field; they will deliver insight into bridging the gap between basic, translational and clinical science. The forum will hopefully inspire and germinate future solid scientific endeavours and help in connecting scientists-clinicians in our field going forward.

Finally, I'd like to thank the entire international 1st World NET Forum scientific committee and our prestigious and stellar international faculty for attending this forum and bringing their expertise to our gathering. Throughout this conference, I ask you to stay engaged and proactive and make use of all the opportunities to exchange, learn and network.

With kind regards,

Dermot O'Toole
ENETS Chairman

On behalf of the 1st World NET Forum Scientific Committee

---

Profile

Ipsen is a global specialty-driven biopharmaceutical company focused on Innovation and Specialty Care.

It develops and commercializes innovative medicines in three key therapeutic areas: Oncology, Neuroscience and Rare Diseases.

Its commitment to oncology is exemplified through its growing portfolio of key therapies for prostate cancer, neuroendocrine tumors, renal cell carcinoma, hepatocarcinoma and pancreatic cancer.

Ipsen also has a well-established Consumer Healthcare business.

Ipsen sells more than 20 drugs in over 115 countries, with a direct commercial presence in more than 30 countries.

Ipsen’s R&D is focused on its innovative and differentiated technological platforms located in the heart of the leading biotechnological and life sciences hubs (Paris-Saclay, France; Oxford, UK; Cambridge, US).

The Company has about 5,800 employees worldwide.

Ipsen is listed in Paris (Euronext: IPN) and in the United States through a Sponsored Level 1 American Depositary Receipt program (ADR: IPSEY).

For more information on Ipsen, visit www.ipsen.com.

2018 Key Figures

20+ drugs marketed in more than 115 countries

More than 3/4 of sales generated by specialty care drugs

We invested € 302.1 million in R&D representing about 13.6% of sales

5800+ employees worldwide

---

Dear Friends and Colleagues,

On behalf of the European Neuroendocrine Tumor Society (ENETS) and our partner NET societies around the world (incl. NANETS, APNETS, COMMNETS, CSNET, CNETS, JNETS, Argentum, NET Initiatives in South America, and INCA), it is a great pleasure to welcome you to this inaugural research event, the 1st World NET Forum - A Forum on Basic, Translational and Global NET Aspects. It is an exciting time for neuroendocrine tumor science as we continue to grow and adapt and innovate. NET societies globally are striving to increase the knowledge surrounding the fundamental scientific aspects pertaining to NET tumors and this forum is aimed at bringing the leading scientists in our field to connect and inspire clinicians and scientists at the cutting edge of NET research.

The 1st World NET Forum will focus on models in NET research, NET tumor biology advances, therapeutic advances in NET and novel areas in NET diagnostics and therapy.

Some of the many highlights awaiting you include keynote speeches on unravelling entero-endocrine differentiation with organoid models, understanding the tumor biology of NEN by integrated genomic analysis, deciphering NET tumor invasiveness to potentiate real therapy candidates, and precision oncological approach in neuroendocrine tumors.

We are delighted and grateful to welcome several leading international NET scientists, who represent a true global perspective in our NET research field; they will deliver insight into bridging the gap between basic, translational and clinical science. The forum will hopefully inspire and germinate future solid scientific endeavours and help in connecting scientists-clinicians in our field going forward.

Finally, I’d like to thank the entire international 1st World NET Forum scientific committee and our prestigious and stellar international faculty for attending this forum and bringing their expertise to our gathering. Throughout this conference, I ask you to stay engaged and proactive and make use of all the opportunities to exchange, learn and network.

With kind regards,

Dermot O’Toole
ENETS Chairman

On behalf of the 1st World NET Forum Scientific Committee